Chen Chen

Cooley advised Degron Therapeutics on intellectual property due diligence matters in connection with its $1.2 billion collaboration agreement with Takeda Pharmaceuticals. Degron and Takeda will collaborate to utilize Degron’s GlueXplorer platform to identify, validate and optimize molecular glue degraders for specific therapeutic targets selected by Takeda.

Cooley advised European life sciences investment firm Medicxi on its strategic $40 million investment in D3 Bio, a Shanghai-based biotechnology company focused on the discovery, development and registration of innovative medicines in oncology and immunology.

Cooley advised Tectonic Therapeutic, a privately held biotechnology company developing G-protein coupled receptor-targeted therapeutic proteins, on its definitive merger agreement to combine in an all-stock transaction with AVROBIO, a gene therapy company with a purpose to free people from a lifetime of genetic disease. Tectonic also obtained $130.7 million in private financing commitments with a syndicate of new and existing leading life sciences investors in connection with the merger.

Cooley advised SystImmune, a clinical-stage biopharmaceutical company, on its exclusive license and collaboration agreement with Bristol Myers Squibb for SystImmune’s BL-B01D1.

Cooley advised Eccogene on its strategic collaboration and license agreement with AstraZeneca, a global biopharmaceutical company. Eccogene will receive an initial upfront payment of $185 million and will also be eligible to receive up to $1.825 billion in future clinical, regulatory and commercial milestones, as well as royalty payments.